Teva Reports Third Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Teva Pharma (TEVA) Misses Q3 EPS by 3c; Lowers Revenue Outlook on FX
November 3, 2022 7:08 AM EDTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.03 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $3.6 billion versus the consensus estimate of $3.85 billion.
GUIDANCE:
Teva Pharma sees FY2022 EPS of $2.40-$2.60, versus the consensus of... More
